ArticleTherapeutic innovation & regulatory science2015
ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder.
Article in Therapeutic innovation & regulatory science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mitochondrial DNA haplogroups and risk of attention deficit and hyperactivity disorder in European Americans.Translational psychiatry · 2020Pooled it
- Amphetamine Use in the Elderly: A Systematic Review of the Literature.Current neuropharmacology · 2020Pooled it
- An electronic health record (EHR) phenotype algorithm to identify patients with attention deficit hyperactivity disorders (ADHD) and psychiatric comorbidities.Journal of neurodevelopmental disorders · 2022Trial
- Trial
- Effects of exposure to lisdexamfetamine dimesylate on hepatic parameters of pubertal rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The impact of social determinants of health and trajectories of medication use on functional outcomes in children with ADHD: study protocol.BJPsych open · 2026Article
- Novel pharmacological targets for GABAergic dysfunction in ADHD.Neuropharmacology · 2024Review
- Sleep disorders related to index and comorbid mental disorders and psychotropic drugs.Annals of general psychiatry · 2023Article
- Current Pharmacological Treatments for ADHD.Current topics in behavioral neurosciences · 2022Review
- Deep learning prediction of attention-deficit hyperactivity disorder in African Americans by copy number variation.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Review
- Which came first: Cannabis use or deficits in impulse control?Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Article
- Methylphenidate for Mild Cognitive Impairment: An Exploratory 3-Day, Randomized, Double-Blind, Placebo-Controlled Trial.Frontiers in medicine · 2021Article
- Non-coding structural variation differentially impacts attention-deficit hyperactivity disorder (ADHD) gene networks in African American vs Caucasian children.Scientific reports · 2020Article
- Article
- Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling.Nature communications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Attention deficit hyperactivity disorder (ADHD) is the most common neurobiological disorder in children, with a prevalence of ~6-7%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.